SEC Form 4 · accession 0001209191-16-151797
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Haqq
Officer — Chief Medical Officer
Period of report
Nov 21, 2016
Accepted (ET)
Nov 22, 2016 · 6:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2016 | S | 7,068 | $17.85 | D | 376,105 | D | |
| Common StockF2 | holding | — | — | — | 17,312 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 2,688 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016.
- F2The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- F3The shares are held by The Havenside Trust, of which the Reporting Person is trustee.